A NEW chemical entity fixed dose combination product has had an Australian Public Assessment Report (AusPAR) posted by the Therapeutic Goods Administration.
Orkambi 200/125 (lumacaftor/ivacaftor) is a cystic fibrosis (CF) treatment from Vertex Pharmaceuticals.
For details see www.tga.gov.au.
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
CAMDEN Day and Night Pharmacy has clinched the top prize in the Pharmacy category at the 2024 Australian Small Business Champion Awards recently.